The semiconductor sector saw activity involving Texas Instruments Inc. (NASDAQ:TXN) recently, specifically concerning a significant transaction by one of its directors. Carrie Smith Cox, who serves as a director for the company, executed sales totaling 8,838 shares of common stock on May 13, 2026. These divestments yielded an aggregate value estimated at $2,708,028.
The execution price for these sold shares varied across a narrow range, falling between $305.91 and $307.24 per share. This timing is particularly noteworthy given the current market position of TXN stock, which is trading near its 52-week high of $310.29. Over the course of the last six months, the shares have experienced a substantial surge, climbing by 96%. In parallel to this price action, some analysis suggests that the stock may be overvalued, with InvestingPro placing it among companies identified on the Most Overvalued list.
Prior to these reported sales, Ms. Cox had been active in acquiring company equity through option exercises. Specifically, she acquired 8,838 shares of Texas Instruments common stock via this mechanism, representing a total value of approximately $947,492. These initial acquisitions were made at lower prices, ranging from $104.41 to $110.15 per share.
Details of Prior Option Exercises
The options exercised by Ms. Cox were structured in two distinct tranches:
- First Tranche: She exercised options to obtain 4,306 shares at a cost of $110.15 per share. These specific options became exercisable over four equal annual installments starting on January 25, 2019, with an expiration date set for January 25, 2028.
- Second Tranche: She also exercised options for 4,532 shares at a price of $104.41 per share. These options were made exercisable in four equal annual installments beginning on January 25, 2020, and carry an expiration date of January 25, 2029.
As a direct result of these transactions, Carrie Smith Cox currently holds a total holding of 37,626 shares of Texas Instruments common stock.
Market Context and Analyst Sentiment
The recent activity by Ms. Cox is set against a backdrop of heightened analyst interest in Texas Instruments following its latest financial reporting cycle. The company reported results that surpassed market expectations, achieving both revenue and earnings per share beats.
According to Benchmark's analysis, the firm noted a revenue beat ranging from approximately $300 million to $335 million, coupled with an increase in earnings per share estimated between $0.32 and $0.34. This positive performance led several major financial institutions to adjust their outlook:
- UBS highlighted a strong free cash flow prognosis, prompting the firm to raise its price target to $295 while maintaining a Buy rating for TXN.
- Truist Securities increased its price target to $278. The analysis emphasized that the demand recovery observed is not limited solely to artificial intelligence and data centers but extends into industrial applications as well.
- Cantor Fitzgerald adjusted its own price target to $300, attributing potential growth drivers to Texas Instruments' established pricing power and robust manufacturing capabilities.
Furthermore, BofA Securities reiterated a Buy rating with a price target of $320. This assessment followed a virtual discussion with the head of investor relations at Texas Instruments, who pointed toward a recovery quality that was better compared to the previous year.
These combined developments paint a picture of positive sentiment among professional analysts, evidenced by multiple firms maintaining favorable ratings and raising their price targets for the semiconductor leader. For investors seeking deeper analysis into TXN’s valuation metrics and performance data, resources are available through InvestingPro.